Sept 28 (Reuters) - Moody’s:
* Moody’s says biosimilars market adoption faces hurdles but development continues apace
* Moody’s says slow launch of Pfizer’s inflectra illustrates hurdles that biosimilar manufacturers face in gaining significant traction in the U.S.
* Moody’s says potential changes to U.S. Medicare reimbursement could further encourage biosimilar adoption
* Moody’s says among biggest reasons for biosimilars’ slow adoption in U.S. is medicare reimburses providers at higher rates for innovator product use
* Moody’s says Medicare reimburses providers at lower rates for switching to the biosimilar from innovator product
* Moody’s says “biosimilar developers still have lots of room for growth, and we expect a number of new approvals over the next 12 to 18 months” Source text for Eikon: Further company coverage: